Cargando…
1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience
Autores principales: | Cui, W., Yousaf, N., Bhosle, J., Minchom, A.R., Ahmed, M., McDonald, F., Locke, I., Lee, R., O'Brien, M., Popat, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506368/ http://dx.doi.org/10.1016/j.annonc.2020.08.1812 |
Ejemplares similares
-
Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience
por: Cui, Wanyuan, et al.
Publicado: (2020) -
180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19
por: Cui, W., et al.
Publicado: (2021) -
Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications
por: Hindocha, Sumeet, et al.
Publicado: (2021) -
A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma
por: Minchom, Anna, et al.
Publicado: (2019) -
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
por: Joshi, Kroopa, et al.
Publicado: (2021)